Literature DB >> 22583916

Brain functional abnormality in schizo-affective disorder: an fMRI study.

M Madre1, E Pomarol-Clotet, P McKenna, J Radua, J Ortiz-Gil, F Panicali, J M Goikolea, E Vieta, S Sarró, R Salvador, B L Amann.   

Abstract

BACKGROUND: Schizo-affective disorder has not been studied to any significant extent using functional imaging. The aim of this study was to examine patterns of brain activation and deactivation in patients meeting strict diagnostic criteria for the disorder.
METHOD: Thirty-two patients meeting research diagnostic criteria (RDC) for schizo-affective disorder (16 schizomanic and 16 schizodepressive) and 32 matched healthy controls underwent functional magnetic resonance imaging (fMRI) during performance of the n-back task. Linear models were used to obtain maps of activations and deactivations in the groups.
RESULTS: Controls showed activation in a network of frontal and other areas and also deactivation in the medial frontal cortex, the precuneus and the parietal cortex. Schizo-affective patients activated significantly less in prefrontal, parietal and temporal regions than the controls, and also showed failure of deactivation in the medial frontal cortex. When task performance was controlled for, the reduced activation in the dorsolateral prefrontal cortex (DLPFC) and the failure of deactivation of the medial frontal cortex remained significant.
CONCLUSIONS: Schizo-affective disorder shows a similar pattern of reduced frontal activation to schizophrenia. The disorder is also characterized by failure of deactivation suggestive of default mode network dysfunction.

Entities:  

Mesh:

Year:  2012        PMID: 22583916     DOI: 10.1017/S0033291712000943

Source DB:  PubMed          Journal:  Psychol Med        ISSN: 0033-2917            Impact factor:   7.723


  7 in total

1.  Midline Brain Abnormalities Across Psychotic and Mood Disorders.

Authors:  Ramón Landin-Romero; Benedikt L Amann; Salvador Sarró; Amalia Guerrero-Pedraza; Victor Vicens; Elena Rodriguez-Cano; Eduard Vieta; Raymond Salvador; Edith Pomarol-Clotet; Joaquim Radua
Journal:  Schizophr Bull       Date:  2015-07-17       Impact factor: 9.306

Review 2.  The role of default network deactivation in cognition and disease.

Authors:  Alan Anticevic; Michael W Cole; John D Murray; Philip R Corlett; Xiao-Jing Wang; John H Krystal
Journal:  Trends Cogn Sci       Date:  2012-11-08       Impact factor: 20.229

3.  Load-dependent hyperdeactivation of the default mode network in people with schizophrenia.

Authors:  Britta Hahn; Alexander N Harvey; James M Gold; Thomas J Ross; Elliot A Stein
Journal:  Schizophr Res       Date:  2017-01-07       Impact factor: 4.939

4.  Hyperdeactivation of the Default Mode Network in People With Schizophrenia When Focusing Attention in Space.

Authors:  Britta Hahn; Alexander N Harvey; James M Gold; Bernard A Fischer; William R Keller; Thomas J Ross; Elliot A Stein
Journal:  Schizophr Bull       Date:  2016-02-28       Impact factor: 9.306

5.  Multimodal Brain Changes in First-Episode Mania: A Voxel-Based Morphometry, Functional Magnetic Resonance Imaging, and Connectivity Study.

Authors:  José M Goikolea; Danai Dima; Ramón Landín-Romero; Imma Torres; Giuseppe DelVecchio; Marc Valentí; Benedikt L Amann; Caterina Mar Bonnín; Peter J McKenna; Edith Pomarol-Clotet; Sophia Frangou; Eduard Vieta
Journal:  Schizophr Bull       Date:  2019-03-07       Impact factor: 9.306

6.  A group ICA based framework for evaluating resting fMRI markers when disease categories are unclear: application to schizophrenia, bipolar, and schizoaffective disorders.

Authors:  Yuhui Du; Godfrey D Pearlson; Jingyu Liu; Jing Sui; Qingbao Yu; Hao He; Eduardo Castro; Vince D Calhoun
Journal:  Neuroimage       Date:  2015-07-26       Impact factor: 6.556

7.  Potential reporting bias in fMRI studies of the brain.

Authors:  Sean P David; Jennifer J Ware; Isabella M Chu; Pooja D Loftus; Paolo Fusar-Poli; Joaquim Radua; Marcus R Munafò; John P A Ioannidis
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.